# Pharmaceutical Entity Space (𝓔)
## Foundational State Space for Constitutional Pharmaceutical Intelligence

The Pharmaceutical Entity Space \( \mathcal{E} \) is the complete domain of all
pharmaceutical, biomedical, and therapeutic entities over which constitutional
mathematics, WAD arithmetic, and the R³ operator are defined.

Normative reference:  
Russell, “Constitutional Mathematics for Pharmaceutical Reproducibility”
(SSRN‑6816078, May 22, 2026)

---

## 1. Definition

\[
\mathcal{E} = \{ Y \mid Y \text{ is any pharmaceutical, biologic, or nucleic acid entity in composite or refined form} \}
\]

The space includes:

- small‑molecule compounds  
- biologics (mAbs, proteins, peptides)  
- nucleic acid therapeutics (siRNA, ASO, mRNA)  
- prodrug systems  
- precursor mixtures  
- intermediate states  
- refined states  
- fixed‑point states  

Every constitutional operator in the Pharma Domain acts on elements of
\( \mathcal{E} \).

---

## 2. Structural Requirements

Each entity \(Y \in \mathcal{E}\) MUST have:

- a measurable impurity profile  
- a definable structural identity  
- a corresponding HPLC‑MS signature  
- a precursor composition hash  
- a constitutional mapping \(M(Y)\)  
- a refinement history (if applicable)  
- a ledger‑anchored provenance chain  

Entities lacking any of these properties cannot be evaluated under the
constitutional framework.

---

## 3. State Categories

### **3.1 Composite States**
Unrefined or partially refined mixtures:

- precursor blends  
- reaction intermediates  
- crude extracts  
- polymorphic mixtures  
- aggregated biologics  

These states are valid members of \( \mathcal{E} \) but cannot be fixed‑point
members.

---

### **3.2 Proposed States**
Candidate refinement outputs:

\[
Y_p \in \mathcal{E}
\]

Evaluated by:

- Seven Constitutional Axioms  
- F27 component validation  
- R³ recursion  
- impurity threshold  
- gas convergence  

---

### **3.3 Current States**
The state under evaluation at refinement step \(k\):

\[
Y_c = Y_k
\]

Used as the reference point for:

- WAD constraints  
- violation detection  
- ledger anchoring  

---

### **3.4 Fixed‑Point States**
Constitutionally valid pharmaceutical entities:

\[
Y^* \in \mathcal{E} \quad \text{such that} \quad R_3(Y^*) = Y^*
\]

A fixed‑point state MUST satisfy:

- all Seven Axioms  
- all 27 components of F27  
- impurity < 0.1%  
- gas convergence  
- full ledger anchoring  

---

## 4. Constitutional Mapping Domain

The constitutional mapping operator:

\[
M : \mathcal{E} \rightarrow \mathcal{P}(F_{27})
\]

is defined **only** over \( \mathcal{E} \).

If \(Y \notin \mathcal{E}\), then:

- \(M(Y)\) is undefined  
- R³ cannot execute  
- the system MUST emit BLOCK  

---

## 5. WAD Constraint Domain

All WAD‑decidable constraints:

\[
f : \mathcal{E} \times \math
